EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy

Motoki Nakamura iD, Tetsuya Magara, Maki Yoshimitsu, Shinji Kano, Hiroshi Kato, Keisuke Yokota, Katsuhiro Okuda, Akimichi Morita

Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e008441

DOI: 10.1136/jitc-2023-008441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.07.2024. Verfasst von Motoki Nakamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan m…. Hauptthemen laut MEDLINE: Glucosephosphate Dehydrogenase, Immunotherapy, Immunogenic Cell Death. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hori Sciences and Arts Foundation, Japanese Association of Geriatric Dermatology Research, Maruho Takagi Dermatology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enhanced glucose metabolism has been reported in many cancers. Glucose-6-phosphate dehydrogenase (G6PD) is a rate-limiting enzyme involved in the pentose phosphate pathway, which maintains NADPH levels and protects cells from oxidative damage. We recently found that low G6PD expression correlates with active tumor immunity. However, the mechanism involving G6PD and tumor immunity remained unclear.

Methods

We conducted in vitro studies using G6PD-knocked down malignant melanoma cells, pathway analysis using the GEO dataset, in vivo studies in combination with immune checkpoint inhibitors (ICIs) using a mouse melanoma model, and prognostic analysis in 42 melanoma patients and 30 lung cancer patients who were treated with ICIs.

Results

Inhibition of G6PD, both chemically and genetically, has been shown to decrease the production of NADPH and reduce their oxidative stress tolerance. This leads to cell death, which is accompanied by the release of high mobility group box 1 and the translocation of calreticulin to the plasma membrane. These findings suggested that inhibiting G6PD can induce immunogenic cell death. In experiments with C57BL/6 mice transplanted with G6PD-knockdown B16 melanoma cells and treated with anti-PD-L1 antibody, a significant reduction in tumor size was observed. Interestingly, inhibiting G6PD in only a part of the lesions increased the sensitivity of other lesions to ICI. Additionally, out of 42 melanoma patients and 30 lung cancer patients treated with ICIs, those with low G6PD expression had a better prognosis than those with high G6PD expression (p=0.0473; melanoma, p=0.0287; lung cancer).

Conclusion

G6PD inhibition is a potent therapeutic strategy that triggers immunogenic cell death in tumors, significantly augmenting the efficacy of immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucosephosphate DehydrogenaseImmunotherapyImmunogenic Cell DeathAnimalsHumansMiceMelanoma, ExperimentalFemaleMice, Inbred C57BLImmune Checkpoint InhibitorsLung NeoplasmsCell Line, TumorMaleMelanoma

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyMelanomaNon-Small Cell Lung Cancer

Substanzen

Glucosephosphate DehydrogenaseImmune Checkpoint InhibitorsG6PD protein, human

Autor:innen und Institutionen

  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan motoki1@med.nagoya-cu.ac.jp.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan.
  • Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Motoki Nakamura

Förderung

  • Hori Sciences and Arts Foundation
  • Japanese Association of Geriatric Dermatology Research
  • Maruho Takagi Dermatology Foundation

Zitieren

APA

Nakamura, M., Magara, T., Yoshimitsu, M., Kano, S., Kato, H., Yokota, K., Okuda, K., & Morita, A. (2024). Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy. Journal for ImmunoTherapy of Cancer, 12(7), e008441. https://doi.org/10.1136/jitc-2023-008441

Vancouver

Nakamura M, Magara T, Yoshimitsu M, Kano S, Kato H, Yokota K, et al. Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(7):e008441. doi:10.1136/jitc-2023-008441

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Motoki and Magara, Tetsuya and Yoshimitsu, Maki and Kano, Shinji and Kato, Hiroshi and Yokota, Keisuke and Okuda, Katsuhiro and Morita, Akimichi},
  title = {Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {7},
  pages = {e008441},
  doi = {10.1136/jitc-2023-008441}
}
Kostenlos starten →